Literature DB >> 35986225

Predictive value of common genetic variants in idiopathic pulmonary fibrosis survival.

Carlos Daniel Vasconcelos1,2,3, António Carlos Ferreira1,2,3, Patrícia Caetano Mota4,5,6, Miguel Luz Soares1,2,3, Bruno A Lima7, Elisabetta Manduchi8, Jason H Moore9, Natália Melo10, Hélder Novais-Bastos10,1,3, José Miguel Pereira11, Susana Guimarães12, Conceição Souto Moura12, José Agostinho Marques10,1,3, António Morais10,1,3.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown etiology. The role of genetic risk factors has been the focus of numerous studies probing for associations of genetic variants with IPF. We aimed to determine whether single-nucleotide polymorphisms (SNPs) of four candidate genes are associated with IPF susceptibility and survival in a Portuguese population. A retrospective case-control study was performed with 64 IPF patients and 74 healthy controls. Ten single-nucleotide variants residing in the MUC5B, TOLLIP, SERPINB1, and PLAU genes were analyzed. Single- and multi-locus analyses were performed to investigate the predictive potential of specific variants in IPF susceptibility and survival. Multifactor dimensionality reduction (MDR) was employed to uncover predictive multi-locus interactions underlying IPF susceptibility. The MUC5B rs35705950 SNP was significantly associated with IPF: T allele carriers were significantly more frequent among IPF patients (75.0% vs 20.3%, P < 1.0 × 10-6). Genotypic and allelic distributions of TOLLIP, PLAU, and SERPINB1 SNPs did not differ significantly between groups. However, the MUC5B-TOLLIP T-C-T-C haplotype, defined by the rs35705950-rs111521887-rs5743894-rs5743854 block, emerged as an independent protective factor in IPF survival (HR = 0.37, 95% CI 0.17-0.78, P = 0.009, after adjustment for FVC). No significant multi-locus interactions correlating with disease susceptibility were detected. MUC5B rs35705950 was linked to an increased risk for IPF, as reported for other populations, but not to disease survival. A haplotype incorporating SNPs of the MUC5B-TOLLIP locus at 11p15.5 seems to predict better survival and could prove useful for prognostic purposes and IPF patient stratification. KEY MESSAGES : The MUC5B rs35705950 minor allele is associated with IPF risk in the Portuguese. No predictive multi-locus interactions of IPF susceptibility were identified by MDR. A haplotype defined by MUC5B and TOLLIP SNPs is a protective factor in IPF survival. The haplotype may be used as a prognostic tool for IPF patient stratification.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Common genetic variants; Haplotypes; IPF survival; Idiopathic pulmonary fibrosis; MUC5B promoter; TOLLIP

Mesh:

Substances:

Year:  2022        PMID: 35986225     DOI: 10.1007/s00109-022-02242-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   5.606


  12 in total

1.  Toll interacting protein protects bronchial epithelial cells from bleomycin-induced apoptosis.

Authors:  Xiaoyun Li; Sharon E Kim; Ting-Yun Chen; Juan Wang; Xia Yang; Tracy Tabib; Jiangning Tan; Brandon Guo; Sonia Fung; Jing Zhao; John Sembrat; Mauricio Rojas; Sruti Shiva; Robert Lafyatis; Claudette St Croix; Jonathan K Alder; Y Peter Di; Daniel J Kass; Yingze Zhang
Journal:  FASEB J       Date:  2020-06-28       Impact factor: 5.191

2.  Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation.

Authors:  Matthew Stephens; Paul Scheet
Journal:  Am J Hum Genet       Date:  2005-01-31       Impact factor: 11.025

Review 3.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

4.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Authors:  Ganesh Raghu; Bram Rochwerg; Yuan Zhang; Carlos A Cuello Garcia; Arata Azuma; Juergen Behr; Jan L Brozek; Harold R Collard; William Cunningham; Sakae Homma; Takeshi Johkoh; Fernando J Martinez; Jeffrey Myers; Shandra L Protzko; Luca Richeldi; David Rind; Moisés Selman; Arthur Theodore; Athol U Wells; Henk Hoogsteden; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

5.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

6.  Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules.

Authors:  Meng Lv; Yan Liu; Shuli Ma; Zutao Yu
Journal:  Future Med Chem       Date:  2019-10       Impact factor: 3.808

7.  Critical role of serpinB1 in regulating inflammatory responses in pulmonary influenza infection.

Authors:  Dapeng Gong; Kalamo Farley; Mitchell White; Kevan L Hartshorn; Charaf Benarafa; Eileen Remold-O'Donnell
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

8.  TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.

Authors:  Justin M Oldham; Shwu-Fan Ma; Fernando J Martinez; Kevin J Anstrom; Ganesh Raghu; David A Schwartz; Eleanor Valenzi; Leah Witt; Cathryn Lee; Rekha Vij; Yong Huang; Mary E Strek; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

9.  Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis.

Authors:  Haiming Jiang; Yejia Hu; Li Shang; Yuzhu Li; Lihua Yang; Yuguo Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 10.  Toll-Interacting Protein in Pulmonary Diseases. Abiding by the Goldilocks Principle.

Authors:  Xiaoyun Li; Gillian C Goobie; Alyssa D Gregory; Daniel J Kass; Yingze Zhang
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.